Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 25:14:3461-3468.
doi: 10.2147/DDDT.S248850. eCollection 2020.

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma

Kai-Cai Liu #  1 , Ying-Hong Hao #  2 , Wei-Fu Lv  2 , Wei-Dong Jia  3 , Chu-Shu Ji  4 , Chun-Ze Zhou  2 , De-Lei Cheng  2 , Shao-Bao Xu  1 , Zong-Gen Gao  1 , Ming-Xue Su  1 , Chang-Sheng Shi  1
Affiliations

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma

Kai-Cai Liu et al. Drug Des Devel Ther. .

Abstract

Purpose: Transcatheter arterial chemoembolization (TACE) and targeted therapy have become common methods in the treatment of advanced hepatocellular carcinoma (HCC). The purpose of this study was to evaluate the safety and efficacy of TACE combined with sorafenib (TACE-sorafenib) and TACE alone for the treatment of Barcelona clinical stage C HCC.

Methods: The clinical data of 75 patients with BCLC stage C HCC who received TACE-sorafenib or TACE as the initial treatment were retrospectively analyzed. Tumor response, time to progression (TTP), overall survival (OS), and adverse events were compared at 1 month after surgery in the two groups.

Results: One month after treatment, the disease control rate in the TACE-sorafenib group was higher than that in the TACE group alone (82.76% and 57.50%, respectively, P = 0.018). The median values of TTP and OS in the TACE-sorafenib group were longer than those in the TACE group (TTP was 7.6 and 3.4 months, respectively, P = 0.002; OS was 13.6 and 6.3 months, respectively, P = 0.041). The cumulative survival time at 3 months, 6 months, and 1 year was higher in the TACE-sorafenib group than in the TACE group (83.5%, 71.2%, 45.7% vs 57.4%, 40.6%, 21.2%). Sorafenib-related side effects such as hypertension, hand-foot syndrome, and oral ulcers were more common than those in the TACE group alone (P<0.05).

Conclusion: Compared with TACE treatment alone, TACE combined with sorafenib in BCLC-C stage HCC significantly improved disease control rate, TTP, and OS, and no significant increase in adverse reactions was observed.

Keywords: TACE; hepatocellular carcinoma; sorafenib; survival.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest for this work.

Figures

Figure 1
Figure 1
Flow diagram illustrating the treatment process.
Figure 2
Figure 2
(A) Kaplan–Meier survival curves for comparison of OS between TACE + sorafenib group and TACE group (P=0.016). (B) Kaplan–Meier survival curves for comparison of TTP between TACE + sorafenib group and TACE group (P=0.042).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi:10.3322/caac.20107 - DOI - PubMed
    1. Bruix J, Sherman M. American Association for the Study of Liver, D. management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022. doi:10.1002/hep.24199 - DOI - PMC - PubMed
    1. ElSerag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127. doi:10.1056/NEJMra1001683 - DOI - PubMed
    1. Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology. 2015;62:440–451. doi:10.1002/hep.27745 - DOI - PubMed
    1. Sheng J, Qin H, Zhang K, Li B, Zhang X. Targeting autophagy in chemotherapy-resistant of hepatocellular carcinoma. Am J Cancer Res. 2018;8:354–365. - PMC - PubMed

MeSH terms